{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:20:35Z","timestamp":1773296435169,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T00:00:00Z","timestamp":1564790400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T00:00:00Z","timestamp":1564790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00228-019-02730-0","type":"journal-article","created":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T15:02:25Z","timestamp":1564844545000},"page":"1471-1480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["m-TOR inhibitors and risk of Pneumocystis pneumonia after solid organ transplantation: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"75","author":[{"given":"Maryam","family":"Ghadimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zinat","family":"Mohammadpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simin","family":"Dashti-Khavidaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Milajerdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,3]]},"reference":[{"key":"2730_CR1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1086\/515126","volume":"28","author":"SM Gordon","year":"1999","unstructured":"Gordon SM, LaRosa SP, Arroliga AC, Avery RK, Longworth DL (1999) Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 28:240\u2013246. \nhttps:\/\/doi.org\/10.1086\/515126","journal-title":"Clin Infect Dis"},{"key":"2730_CR2","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/00007890-199203000-00019","volume":"53","author":"MR Kramer","year":"1992","unstructured":"Kramer MR, Stoehr C, Lewiston NJ, Starnes VA, Theodore J (1992) Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation--how effective and for how long? Transplantation 53:586\u2013589","journal-title":"Transplantation"},{"key":"2730_CR3","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1128\/CMR.17.4.770-782.2004","volume":"17","author":"M Rodriguez","year":"2004","unstructured":"Rodriguez M, Fishman JA (2004) Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 17:770\u2013782. \nhttps:\/\/doi.org\/10.1128\/CMR.17.4.770-782.2004","journal-title":"Clin Microbiol Rev"},{"key":"2730_CR4","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.4065\/82.9.1052","volume":"82","author":"H Green","year":"2007","unstructured":"Green H, Paul M, Vidal L, Leibovici L (2007) Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82:1052\u20131059. \nhttps:\/\/doi.org\/10.4065\/82.9.1052","journal-title":"Mayo Clin Proc"},{"key":"2730_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD005590.pub3","volume":"1","author":"A Stern","year":"2014","unstructured":"Stern A, Green H, Paul M, Vidal L, Leibovici L (2014) Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 1:1\u201366. \nhttps:\/\/doi.org\/10.1002\/14651858.CD005590.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"2730_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/14651858.CD005590.pub3","volume":"13","author":"N Goto","year":"2011","unstructured":"Goto N, Oka S (2011) P neumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis 13:551\u2013558. \nhttps:\/\/doi.org\/10.1002\/14651858.CD005590.pub3","journal-title":"Transpl Infect Dis"},{"key":"2730_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/ajt.12947","volume":"15","author":"X Iriart","year":"2015","unstructured":"Iriart X, Challan Belval T, Fillaux J, Esposito L, Lavergne RA, Cardeau-Desangles I, Roques O, del Bello A, Cointault O, Lavayssi\u00e8re L, Chauvin P, Menard S, Magnaval JF, Cassaing S, Rostaing L, Kamar N, Berry A (2015) Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis. Am J Transplant 15:190\u2013199. \nhttps:\/\/doi.org\/10.1111\/ajt.12947","journal-title":"Am J Transplant"},{"key":"2730_CR8","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/ajt.12119","volume":"13","author":"S Martin","year":"2013","unstructured":"Martin S, Fishman J (2013) Pneumocystis pneumonia in solid organ transplantation. Am J Transplant 13:272\u2013279. \nhttps:\/\/doi.org\/10.1111\/ajt.12119","journal-title":"Am J Transplant"},{"key":"2730_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/ajt.12119","volume":"5","author":"M Radisic","year":"2005","unstructured":"Radisic M, Lattes R, Chapman J et al (2005) Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case\u2013control study. Transpl Infect Dis 5:84\u201393. \nhttps:\/\/doi.org\/10.1111\/ajt.12119","journal-title":"Transpl Infect Dis"},{"key":"2730_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12735","volume":"19","author":"E Faure","year":"2017","unstructured":"Faure E, Lionet A, Kipnis E, No\u00ebl C, Hazzan M (2017) Risk factors for Pneumocystis pneumonia after the first 6 months following renal transplantation. Transplant Infect Dis 19:e12735. \nhttps:\/\/doi.org\/10.1111\/tid.12735","journal-title":"Transplant Infect Dis"},{"key":"2730_CR11","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1093\/ndt\/gfq689","volume":"26","author":"F Eitner","year":"2011","unstructured":"Eitner F, Hauser IA, Rettkowski O, Rath T, Lopau K, Pliquett RU, Fiedler R, Guba M, Hilgers RD, Floege J, Fischereder M (2011) Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant 26:2013\u20132017. \nhttps:\/\/doi.org\/10.1093\/ndt\/gfq689","journal-title":"Nephrol Dial Transplant"},{"key":"2730_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/TP.0b013e3181aad256","volume":"88","author":"RT Neff","year":"2009","unstructured":"Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC (2009) Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 88:135\u2013141. \nhttps:\/\/doi.org\/10.1097\/TP.0b013e3181aad256","journal-title":"Transplantation"},{"key":"2730_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/j.1469-0691.2009.03143.x","volume":"16","author":"N De Castro","year":"2010","unstructured":"De Castro N, Xu F, Porcher R, Pavie J, Molina J-M, Peraldi M-N (2010) Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case\u2013control study. Clin Microbiol Infect 16:1375\u20131377. \nhttps:\/\/doi.org\/10.1111\/j.1469-0691.2009.03143.x","journal-title":"Clin Microbiol Infect"},{"key":"2730_CR14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/QCO.0b013e32834cac17","volume":"24","author":"AB Reid","year":"2011","unstructured":"Reid AB, Chen SC-A, Worth LJ (2011) Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis 24:534\u2013544. \nhttps:\/\/doi.org\/10.1097\/QCO.0b013e32834cac17","journal-title":"Curr Opin Infect Dis"},{"key":"2730_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ajic.2015.11.012","volume":"44","author":"S Mulpuru","year":"2016","unstructured":"Mulpuru S, Knoll G, Weir C, Desjardins M, Johnson D, Gorn I, Fairhead T, Bissonnette J, Bruce N, Toye B, Suh K, Roth V (2016) Pneumocystis pneumonia outbreak among renal transplant recipients at a north American transplant center: risk factors and implications for infection control. Am J Infect Control 44:425\u2013431. \nhttps:\/\/doi.org\/10.1016\/j.ajic.2015.11.012","journal-title":"Am J Infect Control"},{"key":"2730_CR16","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1097\/00007890-200010270-00021","volume":"70","author":"J Dominguez","year":"2000","unstructured":"Dominguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS (2000) Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial Experience1. Transplantation 70:1244\u20131247","journal-title":"Transplantation"},{"key":"2730_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.trre.2013.06.001","volume":"27","author":"VR Peddi","year":"2013","unstructured":"Peddi VR, Wiseman A, Chavin K, Slakey D (2013) Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transpl Rev 27:97\u2013107. \nhttps:\/\/doi.org\/10.1016\/j.trre.2013.06.001","journal-title":"Transpl Rev"},{"key":"2730_CR18","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Me 6:e1000097. \nhttps:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Me"},{"key":"2730_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00038-008-7068-3","volume":"53","author":"CO Schmidt","year":"2008","unstructured":"Schmidt CO, Kohlmann T (2008) When to use the odds ratio or the relative risk? Int J Public Health 53:165\u2013167. \nhttps:\/\/doi.org\/10.1007\/s00038-008-7068-3","journal-title":"Int J Public Health"},{"key":"2730_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00787-010-0087-7","volume":"19","author":"M Szumilas","year":"2010","unstructured":"Szumilas M (2010) Explaining odds ratios. J Can Acad Child Adolesc Psychiatry 19:227","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"2730_CR21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603\u2013605. \nhttps:\/\/doi.org\/10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"2730_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312. \nhttps:\/\/doi.org\/10.1016\/0197-2456(95)00134-4","journal-title":"Control Clin Trials"},{"key":"2730_CR23","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions. Wiley, Chichester"},{"key":"2730_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Bmj 315:629\u2013634. \nhttps:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"Bmj"},{"key":"2730_CR25","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.1399-3046.2005.00325.x","volume":"9","author":"E Renoult","year":"2005","unstructured":"Renoult E, Buteau C, Lamarre V, Turgeon N, Tapiero B (2005) Infectious risk in pediatric organ transplant recipients: is it increased with the new immunosuppressive agents? Pediatr Transplant 9:470\u2013479. \nhttps:\/\/doi.org\/10.1111\/j.1399-3046.2005.00325.x","journal-title":"Pediatr Transplant"},{"key":"2730_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2165\/00002018-200528020-00006","volume":"28","author":"DR Kuypers","year":"2005","unstructured":"Kuypers DR (2005) Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 28:153\u2013181. \nhttps:\/\/doi.org\/10.2165\/00002018-200528020-00006","journal-title":"Drug Saf"},{"key":"2730_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2165\/00003495-200767030-00004","volume":"67","author":"JJ Augustine","year":"2007","unstructured":"Augustine JJ, Bodziak KA, Hricik DE (2007) Use of sirolimus in solid organ transplantation. Drugs 67:369\u2013391. \nhttps:\/\/doi.org\/10.2165\/00003495-200767030-00004","journal-title":"Drugs"},{"key":"2730_CR28","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.drudis.2015.05.006","volume":"20","author":"DJA Moes","year":"2015","unstructured":"Moes DJA, Guchelaar H-J, de Fijter JW (2015) Sirolimus and everolimus in kidney transplantation. Drug Discov Today 20:1243\u20131249. \nhttps:\/\/doi.org\/10.1016\/j.drudis.2015.05.006","journal-title":"Drug Discov Today"},{"key":"2730_CR29","doi-asserted-by":"publisher","first-page":"e12942","DOI":"10.1111\/tid.12942","volume":"20","author":"MG de Boer","year":"2018","unstructured":"de Boer MG, Walzer P, Mori S (2018) Healthcare related transmission of Pneumocystis pneumonia: from key insights towards comprehensive prevention. Transpl Infect Dis 20:e12942. \nhttps:\/\/doi.org\/10.1111\/tid.12942","journal-title":"Transpl Infect Dis"},{"key":"2730_CR30","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/cid\/ciy682","volume":"68","author":"S Hosseini-Moghaddam","year":"2019","unstructured":"Hosseini-Moghaddam S, Shokoohi M, Singh G et al (2019) A multicenter case-control study of the effect of acute rejection and Cytomegalovirus infection on Pneumocystis pneumonia in solid organ transplant recipients. Clin Infect Dis 68:1320\u20131326. \nhttps:\/\/doi.org\/10.1093\/cid\/ciy682","journal-title":"Clin Infect Dis"},{"key":"2730_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12876","volume":"20","author":"W Werbel","year":"2018","unstructured":"Werbel W, Ison M, Angarone M, Yang A, Stosor V (2018) Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation. Transpl Infect Dis 20:e12876. \nhttps:\/\/doi.org\/10.1111\/tid.12876","journal-title":"Transpl Infect Dis"},{"key":"2730_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12709","volume":"19","author":"YN Hu","year":"2017","unstructured":"Hu YN, Lee NY, Roan JN, Hsu CH, Luo CY (2017) High dose calcineurin inhibitor free everolimus as a maintenance regimen for heart transplantation may be a risk factor for Pneumocystis pneumonia. Transpl Infect Dis 19:e12709. \nhttps:\/\/doi.org\/10.1111\/tid.12709","journal-title":"Transpl Infect Dis"},{"key":"2730_CR33","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/TP.0b013e3182a1618c","volume":"15","author":"AA Rostved","year":"2013","unstructured":"Rostved AA, Sassi M, Kurtzhals JA et al (2013) Outbreak of pneumocystis pneumonia in renal and liver transplant patients caused by genotypically distinct strains of Pneumocystis jirovecii. Transplantation 15:834\u2013842. \nhttps:\/\/doi.org\/10.1097\/TP.0b013e3182a1618c","journal-title":"Transplantation"},{"key":"2730_CR34","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/j.1469-0691.2009.03143.x","volume":"16","author":"XF Castro Nd","year":"2010","unstructured":"Castro Nd XF, Porcher R, Pavie J, Molina J, Peraldi M (2010) Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case-control study. Clin Microbiol Infect 16:1375\u20131377. \nhttps:\/\/doi.org\/10.1111\/j.1469-0691.2009.03143.x","journal-title":"Clin Microbiol Infect"},{"key":"2730_CR35","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","volume":"356","author":"Kahan BD, Group RUS","year":"2000","unstructured":"Kahan BD, Group RUS (2000) Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 356:194\u2013202. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(00)02480-6","journal-title":"Lancet"},{"key":"2730_CR36","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","volume":"67","author":"CG Groth","year":"1999","unstructured":"Groth CG, B\u00e4ckman L, Morales J-M et al (1999) Sirolimus (rapamycin)-based therapy in human renal transplantation: Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67:1036\u20131042","journal-title":"Transplantation"},{"key":"2730_CR37","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","volume":"377","author":"K Budde","year":"2011","unstructured":"Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377:837\u2013847. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(10)62318-5","journal-title":"Lancet"},{"key":"2730_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12984","volume":"20","author":"D Neofytos","year":"2018","unstructured":"Neofytos D, Hirzel C, Boely E, Lecompte T, Khanna N, Mueller NJ, Boggian K, Cusini A, Manuel O, van Delden C, Swiss Transplant Cohort Study (2018) Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss transplant cohort. Transpl Infect Dis 20:e12984. \nhttps:\/\/doi.org\/10.1111\/tid.12984","journal-title":"Transpl Infect Dis"},{"key":"2730_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13737-015-0028-6","volume":"4","author":"HT Silva","year":"2015","unstructured":"Silva HT, Felipe CR, Pestana JO (2015) Reviewing 15 years of experience with sirolimus. Transplant Res 4:6\u201311. \nhttps:\/\/doi.org\/10.1186\/s13737-015-0028-6","journal-title":"Transplant Res"},{"key":"2730_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13464","volume":"33","author":"H Tedesco-Silva","year":"2019","unstructured":"Tedesco-Silva H, del Carmen RM, Cruz Santiago J, Mazzali M, Pacheco-Silva A, Torres R (2019) Optimizing the clinical utility of sirolimus-based immunosuppression for kidney transplantation. Clin Transpl 33:e13464. \nhttps:\/\/doi.org\/10.1111\/ctr.13464","journal-title":"Clin Transpl"},{"key":"2730_CR41","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.transproceed.2011.01.174","volume":"43","author":"B Baur","year":"2011","unstructured":"Baur B, Oroszlan M, Hess O, Carrel T, Mohacsi P (2011) Efficacy and safety of sirolimus and everolimus in heart transplant patients: a retrospective analysis. Transplant Proc 43:1853\u20131861. \nhttps:\/\/doi.org\/10.1016\/j.transproceed.2011.01.174","journal-title":"Transplant Proc"},{"key":"2730_CR42","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1016\/j.transproceed.2008.09.049","volume":"40","author":"J Moro","year":"2008","unstructured":"Moro J, Almenar L, Mart\u00ednez-Dolz L, S\u00e1nchez-L\u00e1zaro I, Ag\u00fcero J, Salvador A (2008) Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation. Transplant Proc 40:3034\u20133036. \nhttps:\/\/doi.org\/10.1016\/j.transproceed.2008.09.049","journal-title":"Transplant Proc"},{"key":"2730_CR43","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","volume":"14","author":"J Klawitter","year":"2015","unstructured":"Klawitter J, Nashan B, Christians U (2015) Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf 14:1055\u20131070. \nhttps:\/\/doi.org\/10.1517\/14740338.2015.1040388","journal-title":"Expert Opin Drug Saf"},{"key":"2730_CR44","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1093\/ndt\/gfr048","volume":"26","author":"GH Struijk","year":"2011","unstructured":"Struijk GH, Gijsen AF, Yong SL, Zwinderman AH, Geerlings SE, Lettinga KD, van Donselaar-van der Pant KAMI, ten Berge IJM, Bemelman FJ (2011) Risk of Pneumocystis jiroveci pneumonia in patients long after renal transplantation. Nephrol Dial Transplant 26:3391\u20133398. \nhttps:\/\/doi.org\/10.1093\/ndt\/gfr048","journal-title":"Nephrol Dial Transplant"},{"key":"2730_CR45","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1399-3062.2012.00739.x","volume":"14","author":"JA McKinnell","year":"2012","unstructured":"McKinnell JA, Cannella AP, Kunz DF et al (2012) Pneumocystis pneumonia in hospitalized patients: a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIV-uninfected persons. Transpl Infect Dis 14:510\u2013518. \nhttps:\/\/doi.org\/10.1111\/j.1399-3062.2012.00739.x","journal-title":"Transpl Infect Dis"},{"key":"2730_CR46","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1399-3062.2011.00645.x","volume":"13","author":"MG de Boer","year":"2011","unstructured":"de Boer MG, Kroon FP, le Cessie S, de Fijter JW, van Dissel JT (2011) Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis 13:559\u2013569. \nhttps:\/\/doi.org\/10.1111\/j.1399-3062.2011.00645.x","journal-title":"Transpl Infect Dis"},{"key":"2730_CR47","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1086\/513988","volume":"175","author":"HS Oz","year":"1997","unstructured":"Oz HS, Hughes WT (1997) Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 175:901\u2013904. \nhttps:\/\/doi.org\/10.1086\/513988","journal-title":"J Infect Dis"},{"key":"2730_CR48","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1399-3062.2012.00740.x","volume":"14","author":"E Wang","year":"2012","unstructured":"Wang E, Partovi N, Levy R, Shapiro R, Yoshida E, Greanya E (2012) Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past. Transpl Infect Dis 14:519\u2013525. \nhttps:\/\/doi.org\/10.1111\/j.1399-3062.2012.00740.x","journal-title":"Transpl Infect Dis"},{"key":"2730_CR49","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/ki.2013.212","volume":"84","author":"JR Chapman","year":"2013","unstructured":"Chapman JR, Marriott DJ, Chen SC-A, MacDonald PS (2013) Post-transplant Pneumocystis jirovecii pneumonia\u2014a re-emerged public health problem? Kidney Int 84:240\u2013243. \nhttps:\/\/doi.org\/10.1038\/ki.2013.212","journal-title":"Kidney Int"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02730-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02730-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02730-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T23:30:09Z","timestamp":1596324609000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02730-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,3]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2730"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02730-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,3]]},"assertion":[{"value":"19 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}